妇科肿瘤协作组第五届卵巢癌共识会议:一线干预
2015年11月在日本东京召开的第五届卵巢癌共识会议,针对卵巢癌患者一线治疗形成推荐:一线临床试验应区分初次减瘤手术与接受新辅助化疗的患者亚组;晚期卵巢癌标准化疗为静脉卡铂联合紫杉醇每3周方案;一线试验首选总生存期为主要终点,无进展生存期可作为替代终点但须同时测量总生存期并辅以其他终点。
要点
- 一线卵巢癌临床试验应按初次减瘤手术与接受新辅助化疗分亚组,并按术后残留病变分层。
- 晚期卵巢癌标准化疗为静脉卡铂联合紫杉醇每3周方案。
- 一线试验首选总生存期为主要终点;若选无进展生存期,须同时测量总生存期并辅以其他终点。
核心结论
- 会议推荐:一线卵巢癌临床试验应区分初次减瘤手术与接受新辅助化疗的患者亚组,并按术后残留病变分层;晚期卵巢癌标准化疗为静脉卡铂联合紫杉醇每3周方案;一线试验首选总生存期为主要终点。
研究设计与样本
- 第五届卵巢癌共识会议于2015年11月在日本东京召开,由妇科肿瘤协作组(Gynecologic Cancer InterGroup)组织,形成关于卵巢癌一线治疗的共识声明。
主要发现
- 手术方面:一线卵巢癌临床试验应考虑的亚组为(a)接受初次减瘤手术的患者和(b)接受新辅助化疗的患者,术后残留病变量应进一步将患者分层为无肉眼残留病变和其他。
- 化疗对照臂方面:晚期卵巢癌的标准方案为静脉卡铂联合紫杉醇每3周方案。
- 可接受的替代方案包括每周紫杉醇联合每3周卡铂、在每3周卡铂联合紫杉醇基础上加用贝伐珠单抗、以及腹腔内治疗;当试验提供一种以上方案时,这些应作为分层变量。
- 试验终点方面:总生存期是首选主要终点,无论一线临床试验是否包含维持治疗部分。
- 无进展生存期(PFS)是替代主要终点,但若选择PFS,必须将总生存期作为次要终点测量,且PFS必须得到额外终点支持,包括预设的患者报告结局和至首次或第二次后续治疗的时间。
关键数值与推荐
- 一线卵巢癌临床试验应区分初次减瘤手术与接受新辅助化疗的患者亚组,并按术后残留病变分层为无肉眼残留病变和其他。
- 晚期卵巢癌标准化疗为静脉卡铂联合紫杉醇每3周方案。
- 可接受的替代方案包括每周紫杉醇联合每3周卡铂、每3周卡铂联合紫杉醇加用贝伐珠单抗、以及腹腔内治疗;当试验提供一种以上方案时,这些应作为分层变量。
- 一线临床试验首选总生存期为主要终点;若选择无进展生存期为主要终点,必须将总生存期作为次要终点测量,并辅以预设的患者报告结局和至首次或第二次后续治疗的时间等额外终点。
- 对于新辅助治疗,应纳入额外的「机会窗」终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo, Japan, in November 2015 are reported. Three topics were reviewed and the following statements are recommended: (i) Surgery: the subgroups that should be considered in first-line ovarian cancer clinical trials should be (a) patients undergoing primary debulking surgery and (b) patients receiving neo-adjuvant chemotherapy. The amount of residual disease following surgery should further stratify patients into those with absent gross residual disease and others. (ii) Control arms for chemotherapy: for advanced stage ovarian cancer the standard is intravenous 3-weekly carboplatin and paclitaxel. Acceptable alternatives, which should be stratified variables in trials when more than one regimen is offered, include weekly paclitaxel plus 3-weekly carboplatin, the addition of bevacizumab to 3-weekly carboplatin and paclitaxel, and intraperitoneal therapy. (iii) Trial Endpoints: overall survival is the preferred primary endpoint for first-line clinical trials with or without a maintenance component. Progression-free survival (PFS) is an alternative primary endpoint, but if PFS is chosen overall survival must be measured as a secondary endpoint and PFS must be supported by additional endpoints, including predefined patient reported outcomes and time to first or second subsequent therapy. For neoadjuvant therapy, additional 'window of opportunity' endpoints should be included.
引用
- Karam A, Ledermann JA, Kim JW, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol. 2017. PMID: 28327917. doi:10.1093/annonc/mdx011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。